Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
An update from ATAI Life Sciences ( (ATAI) ) is now available.
On November 5, 2025, Atai Beckley N.V. completed its acquisition of Beckley Psytech Limited, resulting in a strategic combination to form AtaiBeckley, a global leader in transformative mental health therapies. The acquisition, approved by 98% of shareholders, brings together a robust pipeline of investigational treatments, including a Phase 3-ready asset, BPL-003, and positions the company to potentially transform the treatment landscape for serious mental health conditions. The company is well-financed to fund operations through 2029 and has a strong leadership team in place to execute its mission.
The most recent analyst rating on (ATAI) stock is a Hold with a $5.00 price target. To see the full list of analyst forecasts on ATAI Life Sciences stock, see the ATAI Stock Forecast page.
Spark’s Take on ATAI Stock
According to Spark, TipRanks’ AI Analyst, ATAI is a Neutral.
ATAI Life Sciences’ overall stock score is primarily impacted by its weak financial performance, characterized by ongoing losses and negative cash flows. While technical analysis shows some positive momentum, the valuation remains unattractive due to a negative P/E ratio and lack of dividends. The absence of earnings call data and corporate events means these factors do not influence the score.
To see Spark’s full report on ATAI stock, click here.
More about ATAI Life Sciences
AtaiBeckley N.V. is a clinical-stage biopharmaceutical company focused on developing rapid-acting and convenient mental health treatments. Formed through the strategic combination of atai Life Sciences and Beckley Psytech Limited in November 2025, the company has a pipeline of novel investigational therapies, including BPL-003 for treatment-resistant depression, VLS-01 for TRD, and EMP-01 for social anxiety disorder, all in Phase 2 clinical development.
Average Trading Volume: 6,007,085
Technical Sentiment Signal: Buy
Current Market Cap: $1.38B
For an in-depth examination of ATAI stock, go to TipRanks’ Overview page.